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Abstract: The use of adult myogenic stem cells as a cell therapy for skeletal muscle 
regeneration has been attempted for decades, with only moderate success. Myogenic 
progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates 
for stem cell therapy to regenerate skeletal muscle since they allow allogenic 
transplantation, can be produced in large quantities, and, as compared to adult myoblasts, 
present more embryonic-like features and more proliferative capacity in vitro, which 
indicates a potential for more self-renewal and regenerative capacity in vivo. Different 
approaches have been described to make myogenic progenitors either by gene 
overexpression or by directed differentiation through culture conditions, and several 
myopathies have already been modeled using iPSC-MP. However, even though results in 
animal models have shown improvement from previous work with isolated adult 
myoblasts, major challenges regarding host response have to be addressed  
and clinically relevant transplantation protocols are lacking. Despite these challenges we 
are closer than we think to bringing iPSC-MP towards clinical use for treating human 
muscle disease and sporting injuries. 
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1. Introduction 
Skeletal muscle is a dynamic organ in which an efficient regeneration process ensures repair after 
damage. The process of muscle regeneration creates new myofibers after necrosis resulting from injury 
or a degenerative process. The myonuclei of multinucleated myofibers are post mitotic, arrested in the 
G0 phase of the cell cycle and unable to proliferate. A resident population of adult myogenic stem cells 
called “satellite cells” is the main player in the regeneration process. These cells reside in a quiescent 
state, located between the basal membrane and the plasmalemma of each myofiber. Upon signaling 
from the damaged myofibers, satellite cells become activated, undergo an asymmetric division to  
self-renew, and produce activated myoblasts that are able to proliferate, migrate to the site of injury, 
and fuse with the existing myofibers or to form new myotubes [1]. Besides satellite cells, other 
populations with stem cell properties have been described as capable of undergoing myogenesis and 
contribute to myofiber repair, such as mesangioblasts, bone marrow-derived stem cells, pericytes, or 
interstitial muscle-derived stem cells, though it appears that in vivo they contribute to a much smaller 
extent than satellite cells [2].  
Repeated cycles of myofiber necrosis and regeneration in muscle dystrophies (MD), such as 
Duchenne muscular dystrophy (DMD) and some limb girdle dystrophies, result in exhaustion of 
satellite cell regenerative capacity in humans [3]. Similarly, neuromuscular diseases in which 
neuromuscular junctions are lost and muscles undergo subsequent atrophy, such as spinal muscle 
atrophy (SMA) and familiar amyotrophic lateral sclerosis (ALS), present deficiencies in the satellite 
cells compartment [4,5]. Moreover, the myofibers in both MDs and neuromuscular diseases present 
different abnormalities in their structure and functionality [6–8]. Other situations in which muscle 
regeneration is compromised are severe injury [9] and inflammatory myopathies [3]. Restoration of the 
satellite cell compartment with healthy cells would restore the regenerative capacity of the muscle and 
progressively substitute the defective myofibers. Therefore, in all of these conditions, myogenic cell 
replacement therapy provides a promising perspective for the treatment of degenerative myopathies. 
2. Using Myoblasts as a Cell Therapy 
Transplantation of donor myoblast or satellite cells isolated from healthy individuals has been tried 
extensively in the past with somewhat positive but insufficient results and scarce references to 
functional improvement [10]. In 1995, allogenic normal myoblasts were transferred into the biceps 
brachii arm muscles of DMD patients in order to restore the lack of dystrophin protein [11]. Although 
some fusion of donor nuclei into host myofibers was observed, there was no significant improvement 
in muscle function. Genetic correction has also been explored to allow for autologous transplantation 
of expanded myoblasts, but results again showed engraftment but a low contribution to host  
fibers [12]. Massive death of most of the transplanted cells within a few days after intramuscular 
delivery has been reported by several laboratories [13]. The reasons why the myoblasts die initially are 
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not clear but probably relate to immune aspects, anoikis, and a hostile environment in the host 
damaged muscle. Moreover, using myoblasts as a donor source poses a limitation in the amount of 
original tissue for cell isolation from normal human muscle biopsies. It also limits the possibilities of 
in vitro expansion because myoblasts are limited to a few passages due to senescence and the 
decreased self-renewal capacity of the cells due to the expansion process [14]. Therefore, it is difficult 
to obtain a clinically relevant number of transplantable myoblasts from a donor source. The use of other 
adult stem cells, with high proliferative capacity, as an alternative source of myogenic cells has been 
investigated with disappointing or inconclusive results such as bone marrow-derived stem cells [15], 
pericytes [16], and mesangioblasts [17]. Further research is needed to establish the efficacy of cell 
therapy using these types of donor cells. 
Clinical trials using myogenic cell therapy to treat muscular dystrophies started in the 1990s, 
showed some engraftment of the donor cells but no clear signals of disease recovery or symptom 
alleviation (see Table 1).  
However, extensive preclinical and clinical work over the past few decades has helped to identify 
some relevant issues to address in order to improve cell therapy in muscular dystrophies. The main 
limitations of this therapy are transplanted cell engraftment and contribution to host myofibers, which 
seems to be highly dependent on survival—immunosuppression is thus required but other factors might 
be contributing as well—and migration out of the site of injection. The transplantation regime can also 
affect engraftment success [18].  
Taking all this into account, the ideal donor cell for skeletal muscle regeneration should be easily 
accessible and able to expand extensively without losing myogenic and engraftment capacity, have a 
great survival and fusion rate with host myofibers (high myogenic capacity), and be highly motile to 
spread within the muscle. Moreover, it should contribute to the satellite cell compartment, enabling 
indefinite muscle regenerative capacity. Finally, the ideal myogenic donor cell should have low 
immunogenicity, and be able to be delivered systemically, since intramuscular injection does not seem 
a feasible approach given the large volume of muscle tissue to be treated. 
However, extensive preclinical and clinical work over the past few decades has helped to identify 
some relevant issues to address in order to improve cell therapy in muscular dystrophies. The main 
limitations of this therapy are transplanted cell engraftment and contribution to host myofibers, which 
seems to be highly dependent on survival—immunosuppression is thus required but other factors might 
be contributing as well—and migration out of the site of injection. The transplantation regime can also 
affect engraftment success [18].  
Taking all this into account, the ideal donor cell for skeletal muscle regeneration should be easily 
accessible and able to expand extensively without losing myogenic and engraftment capacity, have a 
great survival and fusion rate with host myofibers (high myogenic capacity), and be highly motile to 
spread within the muscle. Moreover, it should contribute to the satellite cell compartment, enabling 
indefinite muscle regenerative capacity. Finally, the ideal myogenic donor cell should have low 
immunogenicity, and be able to be delivered systemically, since intramuscular injection does not seem 
a feasible approach given the large volume of muscle tissue to be treated. 
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Table 1. Clinical trials using myogenic progenitors for the treatment of Duchenne’s muscular dystrophy. 
Year N Donor Cells Injection Immuno-Suppression Results Conclusions Reference 
1992 4 
Allogeneic 
immunocompatible 
myoblasts 
Intramuscular: tibialis 
anterior, biceps brachii, 
and/or extensor carpi 
radialis longus 
No  
Variable response. Hybrid myofibers 
and modest strength increase in 3 of 
the 4 patient. Slow decay over time. 
No signs of immune 
rejection 
[19]  
1992 8 
Allogeneic 
immunocompatible 
myoblasts 
Intramuscular: tibialis 
anterior 
Cyclosporin 
PCR evidence of hybrid fibers after 1 
moth for 3 patients (1 patient tested 
still positive after 6 months). 
Younger patients with less 
fibrosis presented best 
outcomes 
[20] 
1993 5  Allogenic myoblasts 
Intramuscular: biceps 
brachii, left tibialis 
anterior 
No 
0%–36% hybrid fibers after  
1 month. Low dystrophin expression. 
Strong decrease in hybrid fibers at 6 
months. No functional recovery. 
Transplantation cannot be 
done without  
immuno-suppression 
[21] 
1993 8 Allogeneic myoblasts 
Intramuscular: biceps 
brachii 
Cyclosporin 
Poor functional recovery and lack of 
donor-derived dystrophin. 
Younger donor cells, 
regeneration induction and 
basal laminal fenestration 
could improve results 
[22]  
1993 1 
Asymptomatic twin 
sibling myoblasts 
Intramuscular: extensor 
carpi radialis, biceps 
No 
After 1 year, significant force gain 
(12%–31%) in wrist extension but 
not for elbow flexion. Small increase 
in dystrophin positive and type II 
fibers. 
Small benefit may be due to 
a low level of spontaneous 
muscle regeneration 
[23] 
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Table 1. Cont. 
Year N Donor Cells Injection Immuno-Suppression Results Conclusions Reference 
1995 12 Allogeneic myoblasts 
Intramuscular: biceps 
brachii Injection repeated 
monthly over  
6 months 
With and without 
Cyclosporin 
There was no significant change in 
muscle strength. % of hybrid fiber 
varied between 10.3 (1 patient),  
1 (3) and 0 (8).  
Patient age did not 
correlate with outcome
[11]  
1997 10 
Allogeneic immune-
compatible myoblasts 
Intramuscular: tibialis 
anterior  
Cyclosporin 
Myoblast survival after  
1 month in 3 patients and after 6 
month in 1 patient.  
No recovery symptoms or 
clinically significant dystrophin 
expression. 
- [24]  
2004 3 Allogeneic myoblasts 
Intramuscular: tibialis 
anterior 
Tacrolimus 
Hybrid fibers observed in all 3 
patients (9%, 6%, 8% and 11%) 
- [25]  
2006 9  
Allogeneic immuno-
compatible myoblasts 
Intramuscular Tibalis 
anterior. High density 
injections 
Tacrolimus 
At 4 weeks, 3.5%–26% hybrid 
fibers 
Dystrophin expression 
restricted to injection 
site and mostly in short 
inter-injection distances
[26] 
2007 1 Allogeneic myoblasts 
Intramuscular Thenar 
eminence, biceps brachii 
and gastrocnemius High 
density injections 
Tacrolimus 
At 18 months, 34.5% hybrid 
myofibers in gastrocnemius but 
almost 0% in biceps brachii. 
Increased strength only observed 
in thumb.  
- [27]  
On-going - Mesoan-gioblasts Intra-arterial Tacrolimus Not yet - * 
* EudraCT Number: 2011-000176-33; Sponsor Protocol Number: DMD03; Start Date *: 14 February 2011; Sponsor Name: FONDAZIONE CENTRO S; RAFFAELE DEL MONTE 
TABOR; Full Title: Cell Therapy of Duchenne Muscular Dystrophy by intra-arterial delivery of HLA-identical allogeneic mesoangioblasts. 
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3. Induced Pluripotent Stem Cells (iPSCs)-Derived Myogenic Progenitors (iPSC-MP) 
Embryonic stem cells (ESC) are pluripotent stem cells derived from the inner cell mass of a 
blastocyst that are able to self-renew and to be differentiated in all tissues in the body. Induced PSCs 
share most of the features of ESCs but are derived from adult somatic cells, e.g., dermal fibroblasts, by 
the transient expression of a defined set of reprogramming factors [28]. The fact that iPSCs do not 
involve the destruction of embryos, with the consequent ethical issues, and allow for autologous 
production of the pluripotent cells has opened up an enormous range of possibilities for the 
regenerative cell therapy field. Since iPSCs have limitless replicative capacity in vitro and can 
differentiate into myoblast-like cells, they represent an attractive source of myogenic donors for 
muscle regeneration. Induced PSC-MP also represents a highly valuable tool for in vitro drug testing 
and disease modeling for muscular genetic conditions that were so far limited because of the 
difficulties of obtaining large quantities of tissue. 
Initially, human ESCs (hESCs) proved to be difficult to differentiate into myogenic progenitors, 
probably due to the fact that paraxial mesoderm and subsequently the myogenic program are not  
well recapitulated during embryoid body (EB)—three-dimensional aggregates of pluripotent stem 
cells—formation [29]. The first protocols using different sequential culture conditions, including  
a mesenchymal differentiation step, were successful at producing myogenic progenitors capable of 
engrafting in vivo but these protocols were lengthy and inefficient [30]. It has been reported that the 
need for a mesodermal transition previous to a myogenic commitment is determined by the epigenetic 
landscape in human ESCs [31]. Higher efficiency and shorter protocols were designed by 
overexpression of myogenic transcription factors. Pax3 and Pax7 are paired box transcription factors 
that contribute to early striated muscle development and are expressed in the dermatomyotome of 
paraxial mesoderm. Darabi and colleagues showed that inducible expression of Pax3 using viral 
vectors at early EB formation overcame mesoderm patterning restrictions and yielded up to 50% 
myogenic cells within barely a week [29]. Albini et al. described how overexpression of MyoD1—a 
transcription factor that appears after Pax3 and Pax7 in muscle development and in activated satellite 
cells—alone could not induce myogenic commitment directly on hESCs, but concomitant 
overexpression of the chromatin remodeling complex component BAF60C overcame the mesodermal 
transition limitation [32]. In opposition to these results, Rao et al. describe hESC-derived myogenic 
progenitors by inducible lentiviral overexpression of MyoD1 directly on hESC cells, without a 
previous EB formation [33]. 
Other more efficient and genetic modification-free protocols have been described to obtain  
myogenic progenitors from hESCs, such as isolation of the PDGFRα+ population from EB  
derived-paraxial mesoderm [34] or isolation of the SM/C-2.6+—satellite cell-like—population from 
differentiating mouse ESC-derived EB cultured in high serum [35].  
Since the appearance of iPSCs, extensive work has been done to obtain myogenic progenitors with 
a vision to their clinical application and disease modeling (Table 2). The first iPSC-MP came from 
mouse cells using a protocol similar to the one described above for ESC [35], based on spontaneous 
differentiation and sorting of SM/C2.6 positive cells [36]. Similarly, the group of Awaya reported a 
method of deriving mesenchymal cells with myogenic capacity from EB by a protocol based on 
selective enrichment though step-wise culture conditions [37]. The resulting cells showed long-term 
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engraftment in immunocompromised mice pre-injured with cardiotoxin, and evidence of replenishing 
the satellite cell compartment. However, these protocols are long and not very efficient. Using an 
inducible lentiviral expression system, Darabi et al. produced satellite cell-like progenitors by 
overexpression of Pax7—a transcription factor required for somite myogenesis in the embryo and a 
marker for satellite cells in the adult—in EB from mice (miPSCs) and humans (hiPSCs) [38,39]. The 
resulting cells were able to engraft in a mouse model of muscular dystrophy and to produce 
regeneration and restore some muscle strength, and even showed evidence of donor-derived satellite 
cells—by expression of Pax7 and M-cadherin by the capacity of regeneration after a subsequent injury. 
They reported much better proliferative capacity of the myogenic progenitors in vitro and much better 
engraftment as compared to myoblasts. Lentiviral inducible overexpression of Pax3 in iPSCs from 
dystrophin-lacking mice, which were gene corrected with a truncated version of dystrophin  
(μ-utrophin), produced in a similar fashion myogenic progenitors that engrafted, differentiated, and 
repopulated the satellite cell compartment and exhibited neuromuscular synapses [40]. Goudenege and 
colleagues described a two-step protocol consisting of first culturing in a myogenic medium and then 
infecting with an adenovirus expressing MyoD1 that rendered myogenic progenitors able to engraft in 
the muscular dystrophy model mdx mice [41]. Also, using a self-contained, drug-inducible expression 
vector, based on the PiggyBac transposon for overexpression of MyoD1 and an efficient and quick 
conversion of undifferentiated iPSCs into myogenic progenitors with the ability to engraft in 
immunocompromised mice has been described [42]. A limitation on the use of MyoD1 for generating 
myogenic progenitors is the induction of cell cycle arrest when expressed too long at high levels; 
therefore, as an excellent proliferative capacity is needed to expand in vitro and survive in vivo, careful 
dosage and timing are necessary when using this transcription factor.  
Though gene overexpression approaches are fast, efficient, and appropriate to generate myogenic 
precursors for disease modeling, the risk of undesired genetic recombination or reactivation makes 
them unsuitable for a future application in the clinic for regenerative cell therapy. Different ways to 
obtain transplantable myogenic progenitors that do not involve any genetic modification and are still 
efficient and fast have recently been described. Recently, several reports describe other protocols 
without gene overexpression that include high concentrations of bFGF and EGF on free floating 
spheres [32] and, faster and more efficient, the use of GSK3 inhibitors and bFGF [43,44] in one of the 
cases, producing myogenic progenitors that engrafted in immunocompromised mice that contributed to 
the satellite cell pool [43].  
Another way of avoiding introducing exogenous DNA is the transfection of in vitro-synthesized 
mRNA to overexpress the required transcription factors for myogenic conversion. It was recently 
shown as a proof of principle that transfection of MyoD1 mRNA in hiPSCs produced myogenic cells 
with the ability to fully differentiate [45] in vitro. 
Other cells with myogenic potential that are not myoblasts have been derived from iPSCs: the group 
of Tedesco has developed mesangioblast (pericyte progenitors)-like cells that have been tested in 
animal models [46]. 
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Table 2. Protocols for myogenic progenitor derivation from iPSC and in vivo testing. 
Origin Method Myogenic Cells Mice 
Fiber 
Contribution 
Satellite 
Cell 
Ref.
miPSC 
EB on high serum, 
culture on Matrigel+ 
SM/C2.6 Ab+ 
selection 
Myoblast-like 
SM/C2.6+ 
- Irradiated mdx 
mice 
- Intramuscular 
- Cardiotoxin 
- 58% fibers 
positive 
Yes [36]
hiPSC 
EB + general 
differentiation  
+MyoD1 mRNA 
Myoblast-like 
MyoD1+ 
No - - [45]
miPSC 
Inducible Pax7 
expression on EB+ 
PDGFαR+FLK1− 
selection 
Myoblast-like 
PDGFaR+FLK1− 
- Immuno-deficient 
- Intramuscular  
- Cardiotoxin  
- 15%–20% fibers 
positive  
- Functional 
improvement 
NA * [38]
LGMD2D 
hiPSC 
Inducible lentiviral 
MyoD1 on  
iPSC-derived  
MAB-like  
MyoD1 
expressing 
mesangioblast- 
like 
- Immuno-deficient
- Intramuscular (1) 
- Intra-arterial (2) 
- (1) 53% fibers 
positive 
- (2) Muscle 
colonization 
NA [46]
hiPSC 
EB+ITS medium + 
myogenic medium 
Myoblast-like 
MyoD1+, Pax7+, 
Myf 5+  
- Irradiated  
immuno-deficient
- Intramuscular  
- Cardiotoxin  
- 10%–17% fibers 
positive  
Yes [37]
hiPSC 
Inducible Pax7 
expression on EB  
Pax7+  
myoblast-like 
- Immuno-deficient 
control (1) 
- immuno-deficient 
mdx (2) 
- Intramuscular  
- Cardiotoxin (1) 
(1) Yes  
(2) Yes  
(2) Functional 
improvement 
Yes  [39]
DMD **-
hiPSC 
Mesenchyal-like 
lineage 
differentiation 
+adenoviral MyoD1 
expression 
Myoblast-like 
MyoD1+ 
- Mdx mice  
- Intramuscular 
- Cardiotoxin 
Yes NA [41]
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Table 2. Cont. 
Origin Method Myogenic Cells Mice Fiber Contribution 
Satellite 
Cell 
Ref. 
hiPSC 
EB on Matrigel, 
GSK3 inh., 
forskolin, bFGF 
STEMdiff APEL 
medium 
Myoblast-like 
MyoD1+, Pax7+, 
Myf 5+, Gata2+ 
- Immuno-deficient 
- Intramuscular 
- Cardiotoxin 
Yes Yes [44] 
hiPSC 
ITS Medium+ 
GSK3 inh. 
+bFGF+AChR+ 
sorting 
Myoblast-like 
Pax3+, Pax7+ 
No - - [43] 
hiPSC 
Piggyback 
transposon 
inducible MyoD1 
Myoblast-like 
MyoD1+ 
- Immuno-deficient 
diabetic 
- Intramuscular  
- Cardiotoxin 
Low numbers of 
positive fibers 
NA [32] 
miPSC 
dKO 
Inducible Pax3 
expression on EB 
+PDGFαR+FLK1
− selection 
+μUTR gene 
correction 
Myoblast-like 
Pax3+ 
- dKO  
dystrophin—
utrophin mice 
- Immunosuppr 
ession 
- Intramuscular (1) 
- Intra-arterial (1) 
- 20% fibers  
positive (1). 
- Muscle 
colonization (2)  
- Functional 
recovery (1,2) 
Yes [40] 
hiPSC  
BMD &, 
SMA, 
ALS 
Free floating 
spherical culture  
+FGF2, EGF  
Myoblast-like - - - [42] 
* NA = not assessed; ** Duchenne’s Muscular Dystrophy; & Becker’s Muscular Dystrophy; Ref.: Reference. 
4. Disease Modeling 
The different approaches published so far to make myogenic progenitors from hiPSCs are good 
models of myogenesis in vitro, as the produced cells recapitulate the expression of markers observed  
in vivo. They are able to fuse to produce premature myofibers in the animal in vitro and in most cases 
they have been tested in animal models for engrafting and fusion with host fiber. Several reports 
describe the establishment of myogenic cell lines produced from iPSCs from patients with different 
types of muscular dystrophy. Human iPSC-MPs have been established using MyoD1 overexpression 
by a PiggyBac vector on hiPSCs: Miyoshi Myopathy, a distal myopathy caused by mutations in 
DYSFERLIN, patients’ fibroblasts [42], and carnitine palmitoyltransferase II deficiency, is an 
inherited disorder that leads to rhabdomyolysis [47]. Duchenne muscular dystrophy, the most common 
type of MD, is due to a mutation in the dystrophin gene and has been modeled by adenoviral 
expression of MyoD1 [41] and by inducible lentiviral Pax3 overexpression [40]. The group of 
Hosoyama have also described the derivation of myogenic derivatives using their sphere-base culture 
system from hiPSCs from Becker’s muscular dystrophy, spinal muscular atrophy, and amyotrophic 
lateral atrophy [42]. The created cell lines make great tools for drug screening and further research into 
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the molecular mechanisms of the different myopathies, and can be obtained in large quantities with 
minimal patient invasion. 
5. Future Challenges for Clinical Application 
Myogenic progenitors made from iPSCs seem to be a promising candidate for stem cell therapy to 
regenerate skeletal muscle since they can be produced in large quantities and present more  
embryonic-like features, so are probably more motile and proliferative compared to adult myoblasts. 
However, even though results in animal models show an improvement from previous work with 
isolated myoblasts, in terms of fiber contribution and functional recovery [39,41], a clinically relevant 
transplantation protocol still needs to be designed. 
5.1. In Vivo Survival, Engraftment and Migration 
One of the major caveats of myoblast therapy was the massive death after transplantation. The 
inflammatory and immunological response to allogenic transplants probably played a role in the 
survival of the cells and also engraftment, migration, and differentiation [48]. However, myoblast 
death is seen before the onset of the immunological response and in the presence of immunosuppressors or 
for autologous transplantation, where there should be no immune response [21,23]. Also, anoikis and the 
toxic environment from the high oxidant stress that characterizes dystrophic muscles may play a role in 
the survival of cells. These challenges to survival will be encountered by hiPSCs-MP in the same ways 
as purified adult myoblasts. Regarding engraftment, all the published work on hiPSCs-MP in animal 
models shows in vivo engraftment and fusion with host cells, but greater extent is needed for a 
clinically relevant cell therapy protocol. Limited migration from the injection site, in part due to high 
mortality, but also to intrinsic capacity, is another major limitation that iPSC-derived cells must overcome 
to outperform myoblast therapy. Some authors describe iPSC-MP as resembling embryonic more than 
adult myoblasts [31]. The use of two markers expressed during embryogenesis by hypaxial migratory 
myogenic precursors, C-MET and CXCR4, has been proposed to isolate the most migratory fraction of 
hiPSC-MD [49]. Also, beta 1 integrin, expressed in satellite cells, is essential for engraftment [11] and 
can be another migratory phenotype selection marker. 
5.2. Fibrosis 
Another major limitation to regeneration is dense fibrotic tissue. TGF-β1 induces collagen I 
deposition from myogenic cells with subsequent fibrotic tissue formation. Fibrosis limits myoblast 
engraftment as well as motility and this prevents axons from arriving to myofibers. Unfortunately, 
there are no drugs on the market that can overcome fibrosis in MD patients. However, there is a report 
that bone marrow-derived stromal cell transplantation in the muscle of an ischemia model reduced 
fibrosis due to paracrine effects [50]. This inhibitory effect should be studied in hiPSCs-MP if they are 
to be a candidate for use in a clinical setting.  
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5.3. Creating the Perfect Niche 
Tissue engineering can also be of great help for the survival of transplanted myogenic progenitors in 
the hostile environment of a damaged tissue. Creating a three-dimensional niche for the transplanted 
myogenic progenitors that resembles satellite cells’ natural niche in vivo by using biomaterials 
(alginate, collagen, and hyaluran) will conserve the engrafted cells’ homeostasis and allow asymmetric 
division and myogenic commitment [51]. The cells to be transplanted would be seeded in the 3D 
scaffold and a graft generated in vitro. To complete the niche, extracellular matrix components and 
signaling molecules to stimulate proliferation, migration, and angiogenesis should be included. Muscle 
flaps made with decellularized devices from large mammals and synthetic scaffolds complemented with 
an in vitro-produced extracellular matrix from cell cultures derived from the host provide suitable tools 
for translation to the clinic [52]. From the complex set of requirements for skeletal muscle tissue 
engineered implants to function and integrate in vivo, some issues have already been addressed, such 
as restoration of the muscular-tendon junction or vascularization, while others like reinnervation still 
need further work [49]. 
5.4. Genetic Correction vs. Immunocompatible Transplantation 
When addressing genetic origin myopathies, the transplanted cells should contain the correct 
version of the gene. This can be achieved in two ways: by genetic correction of patient-derived cells or 
by allogenic transplantation of immunocompatible donor cells. One of the major features of iPSCs is 
the possibility of generating patient-derived tissues with minor invasion. Several groups have performed 
gene correction on patient iPSCs. iPSC-derived mesangioblasts, from a Limb-Girdle MD patient, in 
which the wild-type alpha-sarcoglycan gene had been restored by lentiviral delivery, engrafted, and 
fused with host fibers when transplanted in nude mice [46]. Lamin A/C (LMNA) has also been 
corrected in laminopathy patient-derived iPSCs using a helper-dependent adenoviral vector, which is 
safer than other viral vector approaches [53]. Duchenne MD iPSCs have also been corrected with  
μ-utrophin using a sleeping beauty transposon system [39]. In any case, gene therapy is still under 
development and a totally safe way of gene correction has still not been demonstrated.  
Another approach is to transplant cells created from a healthy donor that are matched for the main 
antigens in the host immunological rejection, the HLA antigens. An HLA-typed bank of iPSCs could  
be created to provide a source of compatible donor cells for the individual patients. A relatively small 
number of donors can provide an acceptable match to a high percentage of the population [54]. This 
approach would also be more feasible as a therapeutic approach than the expensive and  
time-consuming generation of personalized iPSC-MP. 
It is necessary to take into account that in the case of genetic diseases that lack the native protein, its 
expression from the grafted tissue will most likely induce a considerable immune response that needs 
to be carefully addressed. 
5.5. Delivery Route 
Moreover, the desirable myogenic progenitor should be able to cross the blood barrier to allow  
for systemic delivery. Treatment of local damage could be done by local intramuscular injections  
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or bio-engineered grafts, but for a cell therapy for MD, SMA, and ALS, in which all muscles in the 
body are affected, a systemic delivery is necessary. Very few reports show successful engraftment 
after intra-arterial delivery [38,39,46]. The adequate dosage and regime of injections still needs  
further study. 
5.6. Safety 
For all the reported work in humans and animals models using muscle stem cells, neither adverse 
side effect has been described, nor colonization in other organs when systemically delivered [39]. 
Also, for iPSC-MP no teratoma formation has been detected [37,39]. However, the double 
reprogramming process—first to pluripotency and then to myogenic lineage—bring along the risk of 
chromosomal abnormalities and genetic instability [55]. Darabi et al. described how, from several 
clones tested for in vivo engraftment and fiber contribution, those that performed better were the ones 
with a normal karyotype [38]. In this sense, chromosomal, genetic, and epigenetic studies must be 
performed on the cells to be transplanted before taking them to the clinic application. Also, 
reprogramming and differentiation methods should not include exogenous DNA but use, for example, 
mRNA transfection; the use of the oncogene c-Myc should be avoided when reprogramming for 
clinical applications. Genes involved in epigenetic remodeling [56] and cell cycle regulation [57] have 
been proposed as alternatives to c-Myc in reprogramming. In this regard, variants of c-Myc with no 
oncogenic potential such as L-Myc or the W136E c-Myc mutant are also able to induce 
reprogramming to pluripotency with less tumorigenic potential [58]. 
5.7. Clinical Grade Protocols 
Whatever the method of choice is for generating the myogenic progenitors, a clinical grade protocol 
must be designed for the cells to be used in patients. The generation process should not include any 
viral vector or exogenous DNA, should be free of animal products, and should use as far as possible 
defined media to increase reproducibility and comply with good manufacturing procedures. Such a 
protocol has not yet been described for either iPSC generation or the derivation of MP. 
6. Conclusions 
The use of hiPSCs as a source of myogenic progenitors for cell therapy for the treatment of muscle 
degenerative diseases overcomes several of the limitations encountered in adult myoblast therapy:  
(i) easy non-invasive source of donor cells; (ii) unlimited proliferative capacity in vitro, and (iii) better 
performance when tested in mouse models in vivo—possibly because of more embryonic-like features. 
In recent years, several protocols of derivation of myogenic progenitors from iPSCs have been 
described reaching very satisfactory efficiency in a short time. The use of transcription factors (Pax7, 
MyoD1) overexpression or GSK3β inhibitors has contributed greatly in this direction. However, a 
clinical grade protocol still needs to be described, including the definition of safety and genetic 
stability requirements for clinical applications. Also, isolation of the MP presenting the most promising 
features for successful regeneration in vivo could improve the performance of the cell therapy, such as 
selecting cells that are more migratory and proliferative or with the possibility of systemic delivery. 
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Other limitations relating to the host—for example, the inflammatory and immune response and the 
appearance of fibrotic tissue—present a major hurdle to a cell therapy approach. More research with 
selective inhibitors or modulators of these processes is needed, and the use of bioengineering to create a 
3D protective niche for the transplanted cells would contribute to the long-term success of a muscle stem 
cell therapy strategy.  
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